Clinical trial
RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP)…
NCT00370331 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00370331 |
|---|---|
| Title | RAISE: Randomized Placebo-Controlled Idiopathic Thrombocytopenic Purpura (ITP) Study With Eltrombopag |
| Official title | A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP. |
| Acronym | RAISE |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Purpura, Thrombocytopaenic, Idiopathic |
| Intervention type | Drug |
| Interventions | eltrombopag, Placebo |
| Enrollment | 197 |
| Start date | Nov 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Aug 31, 2006 |
| Last update posted | Apr 18, 2017 |
| Countries | Austria, Canada, China, Czechia, Denmark, Finland, France, Germany, Greece, Hong Kong, India, Italy and 13 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: